1. Will JNJ owe billions for Oklahoma’s opioid crisis? — GSK’s anti-BCMA hits goals in multiple myeloma study — Is Amgen going to take over Alexion? — See more on our front page news

    TRY TWO WEEKS OF OUR EMAIL NEWS HEADLINES FOR FREE
    Dismiss Notice
  2. Think you have witnessed fraud?Ask a Whistleblower Attorney -- a chance to discuss whistleblower-related legal issues with practicing whistleblower attorneys.
    Dismiss Notice

Diedre's call

Discussion in 'GlaxoSmithKline' started by Anonymous, Aug 19, 2013 at 3:59 PM.

Tags: Add Tags
  1. Anonymous

    Anonymous Guest

    What a bunch of idiots! Did anyone else pick up on the frustration In Diedre's voice that no one was calling in with questions? Didn't they realize that over 1000 people logged in thru the computer? People couldn't call in because they weren't on their phones!!!!Just when I think they couldn't be stupider!!
     
  2. Anonymous

    Anonymous Guest

    Clearly she hates her teammates! Sounded like she was frustrated and peeved about something on the call. Questions were crap because no one wants to address the real issues as they will be tagged for a bad attitude. Don't forget everyone wants to take on the patient first assessments and simulations to be just like us!

    How about the survey results - not a word.
     
  3. Anonymous

    Anonymous Guest

    The silence she heard was the sound of a ship sinking into the water. It all starts and ends with the captain honey.
     
  4. Anonymous

    Anonymous Guest

    she sure didn't like someone asking if assessments and sims were still the most effective way to assess reps. she went off on that...mostly because she has gone through great pains to say it was HER idea.
     
  5. Anonymous

    Anonymous Guest

    The edge in her voice became very noticeable after that question asking if there would be changes to Patient First. She defended PF like a lioness with her cubs. I guess if PF fails then DC goes down too?
     
  6. Anonymous

    Anonymous Guest

    Be kind, her days are numbered.
     
  7. Anonymous

    Anonymous Guest

    Absolutely 100% correct---- and this is the reason it will not change until she is gone. Once Breo tanks it may be the beginning of "why is this happening" for higher ups. Up until now she is perceived as keeping the ship sailing and also hurdling the government restrictions that were placed on the company-----if they knew the storm that was brewing within this organization changes would be made that could keep us in line with the CIA agreement but not so ridiculous to make everyone totally detached. The CIA agreement is available online and once it is read it becomes obvious that they are doing much more than necessary at the expense of its employees. The employee survey should have given them a good clue but loss money from a failed launch speaks much louder.
     
  8. Anonymous

    Anonymous Guest

    Total disdain for her teammates is what I heard in her voice. Perhaps she knows the field can't stand her beloved program of test taking and simulations but she is so hard headed that her attitude is its her way or the highway. Either way the call was further verification of the crap hole direction we have been led into. Steve Sons and HR play a big role in all this too - they have never sold a dose/script of anything yet they can tell everyone else how it is done - right.
     
  9. Anonymous

    Anonymous Guest

    Just wait.
     
  10. Anonymous

    Anonymous Guest

    My take on the call was this...CIA is the reason for PF. Once CIA is over, (3 more yrs or so) then PF will be altered or removed. I also liked the fact that the bulk of sales comes from the U.S. and that the trend will continue until 2020. Tells me that if the country is producing the bulk of the business, then layoffs will occur in other nations who are not performing as well in order to cut costs. (no i am not the PR person everyone keeps referencing). Just looking at the facts.

    One other point/question for all the negative naysayers, if there is no sales force, then there are no FLL, SLL, VP's of sales etc. Do you really believe that a company such as ours will not have a marketing/sales department? At some point you have to look at the reality of it. Our company is actually very healthy. Could there be a downsizing? Sure. But not of the magnitude many of you fear. My division is particularly lean. Throw in normal attrition over the next couple of years and we are even that much more trim. Bottom line, go do your job!
     
  11. Anonymous

    Anonymous Guest

    If our company is so healthy then why was our debt just downgraded a few weeks ago? Advair is gone soon and it makes up 50% of our sales in the US. These new products are niche drugs and will not come close to filling in the gap of a generic Advair.

    I don't see layoffs either but things are NOT good. Let's not forget national healthcare and it's impacts. Keep drinking the kool aid pal. I'll stick to reality and the facts.
     
  12. Anonymous

    Anonymous Guest


    Please keep us updated on Patient First China Edition
     
  13. Anonymous

    Anonymous Guest

    Facts? Perhaps you can provide us a link to the company that has filed a generic to Advair in the US. Do you even understand what would be required to get a generic approval? Are you aware of all the companies that attempted and failed? Apparently not. You also have no clue as to what caused the change in the Moody's rating. Perhaps you should read before shooting off your mouth so that you don't look like a clown next time.
     
  14. Anonymous

    Anonymous Guest

    Symbicort generic before Advair. I wonder which product the payers will cover?

    Related Patents

    Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

    Combination of a bronchodilator and a steroidal anti-inflammatory drug for the treatment of respiratory disorders
    Patent 5,674,860
    Issued: October 7, 1997
    Inventor(s): Carling; Christer Carl Gustav & Trofast; Jan William
    Assignee(s): Astra Aktiebolag
    Effective amounts of formoterol and/or a physiologically acceptable salt and/or solvate thereof and budesonide are used in combination for simultaneous, sequential or separate administration by inhalation in the treatment of an inflammatory respiratory disorder, such as asthma.
    Patent expiration dates:
    October 7, 2014

    Drug product
    Combination of a bronchodilator and a steroidal anti-inflammatory drug for the treatment of respiratory disorders, as well as its use and the preparation thereof
    Patent 5,972,919
    Issued: October 26, 1999
    Inventor(s): Carling; Christer Carl Gustav & Trofast; Jan William
    Assignee(s): Astra Aktiebolag
    Effective amounts of formoterol (and/or a physiologically acceptable salt and/or solvate thereof) and budesonide are used in combination for simultaneous, sequential or separate administration by inhalation in the treatment of respiratory disorder.
    Patent expiration dates:
    December 17, 2012

    Drug product
     
  15. Anonymous

    Anonymous Guest

    Intelligent?

    The guy or girl is a moron. Denial runs deep in this company. Teva/Pfizer and others have a generic MDI Advair. As for the credit rating we were lowered because we are spending too much money on stock buybacks and massive fines.

    I read the Moody's report. Your credit doesn't get downgraded when the company in a position of financial strength. It means conditions are worsening. Typical ivory tower tool.
     
  16. Anonymous

    Anonymous Guest

    nobody wants to ask questions because the culture now created in this company by senior leadership discourages anyone to challenge things because they are branded as negative. That's why the survey results were swept under the rug. This company should change one of the key values to hypocrisy because transparency is really a joke.
     
  17. Anonymous

    Anonymous Guest

    Yes, you are the moron. No one has even filed a product yet and the FDA has not even determined what would be required to determine equivalency. You got caught before looking like a clown and now you are making yourself look even worse.
     
  18. Anonymous

    Anonymous Guest


    Unfortunately, the FDA will be changing their definition of bioequivalence to allow generic incursion. make it easier for the generic company to compete
     
  19. Anonymous

    Anonymous Guest

    Thank you son of Nostrodamas.
     
  20. Anonymous

    Anonymous Guest

    You still have no clue what you are talking about. The definition has not been, nor will ever be changed. Instead, the clinical data requirements can vary from product to product. With simple products, such as immediate release oral drugs, simple blood studies are sufficient. Drug with alternate route of delivery or other unique actions typically require FDA guidance on what will be required. At this point, there has not been any clear guidance, despite attempts by very large generic companies. Even if some guidance magically comes out today, it will take years of development and clinical work before we would even see a submission and then approval on generics are taking 2+ years after submission.

    Like always, we see posts like this person that makes comments that lack facts and demonstrate low intellect.